A detailed history of Theleme Partners LLP transactions in Moderna, Inc. stock. As of the latest transaction made, Theleme Partners LLP holds 7,226,861 shares of MRNA stock, worth $295 Million. This represents 28.47% of its overall portfolio holdings.

Number of Shares
7,226,861
Previous 7,226,861 -0.0%
Holding current value
$295 Million
Previous $858 Million 43.72%
% of portfolio
28.47%
Previous 42.67%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$101.21 - $166.61 $9.61 Million - $15.8 Million
-94,936 Reduced 1.3%
7,226,861 $858 Million
Q1 2024

May 14, 2024

SELL
$85.37 - $115.44 $2.36 Million - $3.19 Million
-27,659 Reduced 0.38%
7,321,797 $780 Million
Q4 2023

Feb 13, 2024

BUY
$69.51 - $104.43 $31.4 Million - $47.2 Million
451,844 Added 6.55%
7,349,456 $731 Million
Q3 2023

Nov 13, 2023

BUY
$96.41 - $126.61 $62.8 Million - $82.4 Million
651,113 Added 10.42%
6,897,612 $712 Million
Q2 2023

Aug 11, 2023

BUY
$118.5 - $160.53 $15.9 Million - $21.5 Million
134,065 Added 2.19%
6,246,499 $759 Million
Q1 2023

May 12, 2023

BUY
$135.66 - $197.02 $34.4 Million - $50 Million
253,576 Added 4.33%
6,112,434 $939 Million
Q4 2022

Feb 10, 2023

SELL
$118.38 - $210.04 $17.2 Million - $30.6 Million
-145,548 Reduced 2.42%
5,858,858 $1.05 Billion
Q3 2022

Nov 14, 2022

SELL
$118.07 - $194.18 $41.3 Million - $68 Million
-350,000 Reduced 5.51%
6,004,406 $710 Million
Q2 2022

Aug 12, 2022

BUY
$117.13 - $176.59 $2.05 Million - $3.08 Million
17,466 Added 0.28%
6,354,406 $908 Million
Q1 2022

May 13, 2022

BUY
$126.46 - $235.05 $166 Million - $309 Million
1,314,766 Added 26.18%
6,336,940 $1.09 Billion
Q4 2021

Feb 11, 2022

BUY
$225.82 - $368.51 $241 Million - $393 Million
1,065,100 Added 26.92%
5,022,174 $1.28 Billion
Q3 2021

Nov 15, 2021

SELL
$221.9 - $484.47 $469 Million - $1.02 Billion
-2,114,982 Reduced 34.83%
3,957,074 $1.52 Billion
Q2 2021

Aug 13, 2021

SELL
$129.91 - $234.98 $29.9 Million - $54 Million
-230,000 Reduced 3.65%
6,072,056 $1.43 Billion
Q1 2021

May 13, 2021

BUY
$109.18 - $185.98 $105 Million - $178 Million
958,358 Added 17.93%
6,302,056 $825 Million
Q4 2020

Feb 12, 2021

SELL
$65.74 - $169.86 $152 Million - $392 Million
-2,309,280 Reduced 30.17%
5,343,698 $558 Million
Q3 2020

Nov 13, 2020

SELL
$54.34 - $94.85 $48.6 Million - $84.8 Million
-893,941 Reduced 10.46%
7,652,978 $541 Million
Q2 2020

Aug 14, 2020

SELL
$29.67 - $80.0 $11.4 Million - $30.7 Million
-384,000 Reduced 4.3%
8,546,919 $549 Million
Q1 2020

May 15, 2020

BUY
$17.78 - $31.58 $44.3 Million - $78.7 Million
2,490,645 Added 38.67%
8,930,919 $267 Million
Q4 2019

Feb 13, 2020

BUY
$13.93 - $21.28 $89.7 Million - $137 Million
6,440,274 New
6,440,274 $126 Million
Q3 2019

Nov 13, 2019

BUY
$12.26 - $18.07 $21.5 Million - $31.8 Million
1,757,647 Added 45.6%
5,612,445 $89.4 Million
Q2 2019

Aug 14, 2019

SELL
$13.7 - $28.34 $22.4 Million - $46.3 Million
-1,632,513 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$14.45 - $23.7 $7.26 Million - $11.9 Million
502,513 Added 44.47%
1,632,513 $33.2 Million
Q4 2018

Feb 14, 2019

BUY
$13.52 - $18.8 $15.3 Million - $21.2 Million
1,130,000 New
1,130,000 $17.3 Million

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $15.9B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Theleme Partners LLP Portfolio

Follow Theleme Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Theleme Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Theleme Partners LLP with notifications on news.